After 20 years of experience, research, trial and error, and a relentless pursuit of truth, Kenton Gray has built what the healthcare industry would not — and launched Veracor Capital to bring it to the world.
You know the feeling. Sick and tired of feeling sick and tired. You get the bloodwork back and the doctor says everything looks normal — but nothing feels normal. You've tried the prescriptions, the specialists, the protocols. You've been managed. You've been treated. You have never been resolved.
This is not an accident. The United States spends more on healthcare than any nation on earth and produces among the worst chronic health outcomes in the developed world. That is not a broken system. That is a system working exactly as designed — built to treat indefinitely, manage permanently, and profit from the patient who never fully recovers. It does not need to be fixed. It needs to be replaced with what actually works.
The proof is now impossible to ignore. In the years following the pandemic, physicians began reporting something they had never seen at scale: aggressive, fast-moving cancers in young people with no prior history — what many are now calling turbo cancers. Autoimmune disorders appearing in people who had never shown a single symptom. Type 2 diabetes accelerating in demographics that never carried that risk. Long COVID presenting not as a respiratory condition but as multi-system biological dysfunction that the existing model has no framework to explain or resolve. These are not isolated incidents. They are a pattern — and the pattern points directly to systemic signal disruption at a scale the healthcare system was never designed to address.
Meanwhile, U.S. healthcare spending has reached $5.3 trillion annually — up from $4.5 trillion just years prior — consuming 18% of the entire economy while the conditions it is supposed to treat grow worse, faster, and younger. The system is not losing ground slowly. It is collapsing in plain sight. And the opportunity for what replaces it has never been larger.
This is one of the most remarkable moments in the history of human health — not because of a single drug or device, but because decades of breakthrough discovery across genomics, bioenergetics, microbiome science, clinical AI, and continuous physiological monitoring have finally converged to reveal what was always missing. When you set aside profit and control and judge only by truth and results, a completely different picture of human health appears. The confusion lifts. The wrong answers become obvious. And the right ones — the ones the body has been waiting for — finally surface.
Signal-Based Medicine and the Kure Health Ecosystem
Kenton Gray saw that picture before most. Over two decades of clinical operation, he identified the source of the confusion: the body was not malfunctioning. It was being interfered with. Biological dysfunction — the originating signal disruption behind virtually every chronic condition — does not begin as disease. It begins as disruption in the body's own signaling: the biochemical, bioelectrical, and physiological communication systems that govern every function the body performs, from cellular repair to immune response to hormonal regulation. The body already knows what to do. It needs the interference removed so it can do it.
Signal-Based Medicine is the methodology he developed to do exactly that. KureOS is the technology platform that delivers it. Signal Science is the clinical language that unifies it. Together they form the Kure Health ecosystem — the consolidation of every validated healing discipline into One Body, One System, and One Approach to human health. Not a new drug. Not a new category. A new operating system for how health is understood, restored, and maintained.
What Kenton built is so significant — so far beyond what the incumbent system is capable of acknowledging — that a group of industry veterans whose careers have been spent at the highest levels of medicine, military health systems, and capital formation came together to form Veracor Capital and launch the Kure Health Ecosystem Fund. Not to invest in healthcare. To invest in its replacement.
No investor who truly understands what has been built here would want to miss it. This is not another healthcare investment. Across every asset class — real estate, technology, energy, consumer, financials — few opportunities exist where the addressable population is every human being on earth, the problem being solved is the leading driver of economic destruction in the developed world, and the methodology to solve it is proprietary, two decades validated, and already operating. This is one of the most important investments of this generation — in any asset class. The Kure Health Ecosystem Fund is the vehicle for investors who are ready to be part of the most consequential transformation in healthcare in our lifetime. Not to watch it happen. To own a piece of it.
The Kure Ecosystem — Coming Next: The full architecture of what Kenton Gray built — the signal mapping platforms, clinical AI infrastructure, practitioner enablement system, and Signal Science clinical lexicon that together form the most complete Signal-Based Medicine operating environment ever assembled — is detailed in the follow-up article: Inside the Kure Ecosystem: The Operating System for Human Health. Available at veracorcapital.com.
Veracor Capital today announced its formal market launch alongside the appointment of Colonel (Retired) Peter F. Demitry, MD, MPH — Former Assistant Air Force Surgeon General for Modernization and the only Test Pilot Physician in U.S. Air Force history — as Strategic Partner and Chief Medical Officer. The firm simultaneously launched the Kure Health Ecosystem Fund, its $250M flagship growth equity vehicle, announced the Riize Expansion Fund as its first active co-sponsored investment, and advanced negotiations with U.S. Navy veteran and six-time No. 1 Billboard artist B. Taylor as brand ambassador for America's 250th anniversary.
What is Veracor Capital?
Veracor Capital is a veteran-owned, AI-first healthcare private equity firm headquartered in Los Angeles, California, managing the Kure Health Ecosystem Fund — a $250M growth equity vehicle built on Signal-Based Medicine and the Kure Health ecosystem. Founded on the conviction that biological signal interference — disruption of the body's biochemical, bioelectrical, and physiological communication systems — is the signal disruption behind virtually every chronic condition, and that resolving that interference generates both superior clinical outcomes and superior financial returns. Led by Founder Kenton Gray — U.S. Marine Corps veteran and aspiring NASCAR racing competitor — and Strategic Partner Col. (Ret.) Peter F. Demitry, MD.
Why Does the Kure Health Ecosystem Fund Generate Superior Returns? The Signal-Based Medicine Thesis
The conventional healthcare model generates revenue from ongoing treatment. The Kure model generates revenue from resolution. Those are not the same business. They are opposite businesses. In a market actively repricing toward outcomes, one commands a premium exit multiple and one does not. The Kure Health Ecosystem Fund invests in the one that does.
Companies built on the Kure thesis — where patients recover, stay recovered, and return not out of dependency but out of trust — generate higher lifetime customer value, carry lower regulatory and litigation risk, and scale through referral rather than advertising spend. Health outcomes are the evidence the thesis is working. They are not a reason to accept lower returns. They are the reason returns are higher.
What is One Body, One System, One Approach — and what is signal interference?
The healthcare industry has divided the human body into specialties and the human condition into diagnoses — each generating its own treatment revenue. Signal-Based Medicine begins from a different premise: the human body is one interconnected system, and dysfunction begins not as disease but as interference in the body's own biological signaling — the biochemical, bioelectrical, and physiological communication networks that regulate every function from cellular repair to immune response to hormonal balance. Kenton Gray identified these signal disruptions as the originating interference preceding virtually every chronic condition. Remove the interference. Restore the signal. The body resolves the dysfunction it was never meant to carry.
KureOS is the technology stack that identifies, maps, and monitors those signals. Signal Science is the clinical language that standardizes them across every practitioner in the ecosystem. One Body. One System. One Approach.
The $5.3 trillion U.S. healthcare market — part of a $9.8 trillion global system — is at a structural inflection point. The mass migration of physicians from institutional medicine to cash-pay private practice, the rise of AI-driven clinical intelligence, the explosion of GLP-1 adjacency categories, and a consumer population actively reclaiming control of their own health are converging into the largest category-creation opportunity in healthcare in a generation. The Kure Health Ecosystem Fund's portfolio is built to capture this shift through infrastructure no generalist PE firm can access, replicate, or compete with.
Three structural advantages define the Kure Health Ecosystem Fund's edge:
Operator-led underwriting: Every investment is evaluated by a team that has built and operated healthcare companies — not financial analysts applying generic frameworks to a sector they have never worked inside.
Proprietary clinical AI infrastructure: KureOS and the INFORM AI platform — a DOD-developed Oracle-based clinical system co-architected by Dr. Demitry, validated across state-level deployments, and still in active use by the Defense Health Agency — deploy across portfolio companies to drive measurable clinical resolution and defensible data moats.
Veteran-owned mandate with commercial multiplier: SDVOSB certification, federal procurement pathways, and direct access to the 19M-veteran consumer segment — whose above-average healthcare expenditure and documented brand loyalty to veteran-led organizations create a structural distribution advantage that competing funds cannot replicate.
"We built the Kure Health Ecosystem Fund on a single conviction: that the healing arts, unified into One Body, One System, and One Approach, generate returns that symptom management never can. Every company in our portfolio either operates inside the Kure ecosystem or aligns directly with its thesis. We do not underwrite spreadsheets. We underwrite resolution." — Kenton Gray — Founder & CEO, Veracor Group | Managing Partner, Kure Health Ecosystem Fund
Who Leads Veracor Capital and the Kure Health Ecosystem Fund?
Kenton Gray is the Founder and CEO of Veracor Group and Managing Partner of the Kure Health Ecosystem Fund. A United States Marine Corps veteran and aspiring NASCAR racing competitor, he spent 20+ years founding and operating healthcare companies including Kure Health, KureOS, EliteMD, and Operation Kure — the Kure Health ecosystem — before forming Veracor Capital to bring institutional capital to the infrastructure he built.
Kenton Gray brings an investment perspective forged by two decades of building and operating companies inside the healthcare categories the Kure Health Ecosystem Fund targets. Following his service in the United States Marine Corps and his aspiration to compete in NASCAR events (Freedom Motorsports Group, 1999–2010), he founded and scaled Kure Health, EliteMD, KureOS, and Operation Kure — the firm's affiliated 501(c)(3) veteran healthcare nonprofit. Operation Kure is also the foundation for Veracor's long-term vision of a new model of veteran healthcare delivery — beginning with a dedicated veteran care campus designed to bring the full Kure Health ecosystem to the men and women who served. Both entities operate in clean separation from the Kure Health Ecosystem Fund's for-profit investment vehicles in accordance with institutional best practices.
Who is Col. (Ret.) Peter F. Demitry, MD, MPH?
Col. (Ret.) Peter F. Demitry is the Former Assistant Air Force Surgeon General for Modernization, the only Test Pilot Physician in U.S. Air Force history, a Harvard Medical School Chief Resident, and the architect of the NFIM framework and INFORM DOD clinical platform. He serves as Strategic Partner and Chief Medical Officer of Veracor Capital and Chairman of the National Foundation for Integrative Medicine (NFIM).
Col. (Ret.) Peter F. Demitry, MD, MPH brings a credential stack without precedent in private equity medical leadership. As Former Assistant Air Force Surgeon General for Modernization, he oversaw health systems modernization for 330,000+ active duty personnel. He holds the distinction of being the only Test Pilot Physician in U.S. Air Force history, with flight test experience in the F-4, A-10, F-16, and F-15 and over 2,300 fighter hours logged. He completed medical residency and research fellowship at Harvard Medical School, where he was selected as Chief Resident. He is the architect of the NFIM (Nutrition, Fitness, Immune, and Mental Health) framework and co-creator of the INFORM platform — a DOD-developed Oracle-based electronic medical system validated across entire state-level clinical deployments and still in active use by the Defense Health Agency. INFORM is now being commercialized as the AI clinical backbone of the Kure Health ecosystem.
"Signal-Based Medicine is a validated clinical methodology built on the same evidence-based frameworks that protect the U.S. military's most valuable assets. What the Kure Health Ecosystem Fund is commercializing is not a concept — it is a proven operating system that now has the capital infrastructure to scale." — Col. (Ret.) Peter F. Demitry, MD, MPH — Strategic Partner & Chief Medical Officer, Veracor Capital
Structural Note — For-Profit / Nonprofit Separation: Veracor Group's for-profit investment vehicles (Veracor Capital, Kure Health Ecosystem Fund, portfolio companies) are cleanly separated from Operation Kure, the firm's affiliated 501(c)(3) veteran healthcare nonprofit. The for-profit capital engine drives returns. The nonprofit mission arm delivers veteran healthcare access. This structure is the institutional standard for healthcare operators raising capital from family offices and qualified institutional investors.
What Does the Kure Health Ecosystem Fund Invest In?
The Kure Health Ecosystem Fund does not invest across generic healthcare categories. It invests exclusively in companies that operate within or align directly with the Kure Health ecosystem — organized around Signal-Based Medicine, KureOS, and Signal Science. This is not a thematic healthcare fund. It is a vertically integrated capital deployment vehicle for a proprietary ecosystem that already exists, already operates, and is already generating revenue. No other healthcare PE firm in the market has this structure.
Qualified investors may access the Kure Health Ecosystem Fund through four structures — designed to match each investor's preferred vehicle, check size, and engagement model:
LP Interest — Standard limited partner stake in the Kure Health Ecosystem Fund. Accredited investors, $250K minimum.
Co-Investment (SPV) — Deal-by-deal co-investment alongside the fund via dedicated SPV. Qualified purchasers, deal-specific terms.
Direct Investment — Direct equity or structured debt into individual portfolio companies. Institutional / family office, by invitation.
Fund Co-Sponsorship — Lead investor / fund manager co-sponsorship structure. Institutional, as demonstrated by the Riize Expansion Fund.
"The Kure Health Ecosystem Fund does not ask investors to believe in a future. It asks them to participate in a present that is already moving — a fully operational healthcare ecosystem with active portfolio companies, live distribution across 100,000+ retail doors, and a clinical infrastructure built and validated inside the DOD." — Kenton Gray — Managing Partner, Kure Health Ecosystem Fund
First Active Investment: Riize LLC — 100,000+ Doors, 13 Platforms, 90 Days
The Kure Health Ecosystem Fund enters the market with anchor deal proof — the validation institutional investors require before committing capital to a new fund manager. Riize LLC, the fund's first co-sponsored portfolio company, has achieved in 90 days what most consumer health brands spend years attempting — securing approved vendor status with Walmart (4,600+ stores), Circle K (7,300 US stores), 7-Eleven (13,300 US stores), Core-Mark (24,000–45,000+ convenience stores), Sheetz (800+ locations), ExtraMile (1,100+ locations), and Sprouts Farmers Market (400–450 stores).
This is not a pipeline. This is approved vendor status — the result of regulatory compliance, GMP certification, third-party laboratory verification, and formal category review by merchandising teams that evaluate hundreds of products and approve very few. Riize passed every gate. The company carries $2.5 million in ready-to-deploy inventory and has generated 3.2–3.6x ROAS on Amazon on an unoptimized $50/day budget. Capital from the Riize Expansion Fund activates inventory, accelerates paid media across Amazon, TikTok, and Meta, and develops enterprise B2B channels with GardaWorld and Allied Universal.
"When investors look at Riize, they see Walmart, Circle K, and 7-Eleven already saying yes. When they look at the digital side, they see Amazon, TikTok Shop, and Walmart Marketplace live and generating real returns on minimal spend. This is proof of concept already in market — and the Kure Health Ecosystem Fund is the capital engine behind what happens next." — Kenton Gray — Managing Partner, Kure Health Ecosystem Fund
"We didn't build a brand looking for distribution. We built the infrastructure, earned the relationships, and proved the product. The Kure Health Ecosystem Fund is the capital engine to activate what we've already won." — Reilly Schueler — Founder & CEO, Riize LLC
B. Taylor Signature Riize Strip Collection: Veterans, First Responders, and America's 250th
Simultaneously with this firm launch, Veracor Capital and Riize LLC announced advanced negotiations with U.S. Navy veteran, six-time No. 1 Billboard chart artist, and Goodwill Global Ambassador B. Taylor for a co-branded signature strip collection timed to America's 250th anniversary on July 4, 2026. B. Taylor's "We Are One" campaign is produced in direct partnership with the Department of Defense, the Department of Homeland Security, and the VA — and his national "We Are One" Tour reaches military bases, fire stations, first responder communities, and national commemoration events where Riize is already an approved vendor.
The collaboration activates across Riize's full distribution footprint: 100,000+ approved retail doors including Walmart, Circle K, 7-Eleven, and Sprouts Farmers Market, plus live digital storefronts on Amazon, TikTok Shop, Walmart Marketplace, Facebook Shop, Instagram Shop, and YouTube Store.
Market Context: Why Right Now — Disease Explosion, $5.3T U.S. / $9.8T Global, and a $95B PE Market
U.S. healthcare spending reached $5.3 trillion in 2024 — 18% of the entire American economy, up from $4.5 trillion just years prior — while global healthcare spending has crossed $9.8 trillion and is accelerating. At the same time, chronic disease is accelerating in every direction: post-pandemic autoimmune disorders, aggressive cancers presenting in younger and younger patients, metabolic dysfunction reaching populations that were never historically at risk. The system absorbing that spending is not resolving these conditions. It is adding them to its treatment ledger. Every new diagnosis is a new revenue stream. The gap between what is being spent and what is being resolved has never been wider — and that gap is exactly where the Kure Health Ecosystem Fund operates.
Global healthcare private equity deal value reached $95 billion in 2024. Consumer health, Signal-Based Medicine, and healthcare AI captured the fastest-growing share of institutional capital — driven by the mass migration of physicians from institutional medicine to cash-pay private practice, the explosion of GLP-1 adjacency categories, sublingual delivery format adoption, and a consumer population actively reclaiming control of their biological health. These are the exact addressable markets that the Kure Health Ecosystem Fund's portfolio companies serve.
The veteran-owned mandate adds commercial dimension that financial-only funds cannot access. SDVOSB certification, federal procurement pathways, and the documented brand loyalty of 19 million U.S. veterans — a segment with above-average healthcare expenditure and high trust in veteran-led organizations — give Kure Health Ecosystem Fund portfolio companies a structural go-to-market advantage that conventionally managed competitors cannot replicate.
Why is the Kure Health Ecosystem Fund entering the market now?
U.S. healthcare spending reached $5.3 trillion in 2024 — part of a $9.8 trillion global system — while chronic disease accelerates: post-pandemic autoimmune disorders, aggressive cancers in younger patients, metabolic dysfunction at historic scale — all pointing to systemic signal disruption the existing model cannot explain or resolve. The gap between what is being spent and what is being resolved has never been wider. Simultaneously, $95B in global healthcare PE capital is flowing toward resolution-based care, AI-driven clinical infrastructure is reaching commercial maturity, and a distribution environment where Riize LLC achieved 100,000+ approved retail doors and 13 live digital platforms in 90 days demonstrates the velocity of the consumer health shift. The Kure Health Ecosystem Fund exists at the exact intersection of all of it.
About Veracor Capital & the Kure Health Ecosystem Fund
Veracor Capital is a veteran-owned, AI-first healthcare private equity firm headquartered in Los Angeles, California, managing the Kure Health Ecosystem Fund — a $250M growth equity vehicle built on Signal-Based Medicine and the Kure Health ecosystem. Led by Founder & Managing Partner Kenton Gray — U.S. Marine Corps veteran and aspiring NASCAR racing competitor — and Strategic Partner & Chief Medical Officer Col. (Ret.) Peter F. Demitry, MD, MPH, Former Assistant Air Force Surgeon General for Modernization. The firm's for-profit investment vehicles operate in clean separation from Operation Kure, its affiliated 501(c)(3) veteran healthcare nonprofit.
About Veracor Group
Veracor Group is a vertically integrated health technology holding company and parent entity of Kure Health, KureOS, EliteMD, Veracor Capital, and Operation Kure. Its proprietary Signal-Based Medicine framework, KureOS signal mapping platform, and Signal Science clinical lexicon serve as the scientific and technological infrastructure across all portfolio entities — organized around One Body, One System, and One Approach to human health. Veracor Capital operates across two sectors — health and healthcare finance — with additional investment vehicles currently in formation.
About Riize LLC
Riize LLC is a Houston, Texas-based consumer health company and creator of Riize Strips — fast-acting sublingual oral strips delivering nutraceutical formulations across energy, sleep, recovery, GLP-1 support, NAD+, and performance categories. In under 90 days, Riize has secured approved vendor status across Walmart, Circle K, 7-Eleven, Core-Mark, Sheetz, ExtraMile, Sprouts Farmers Market, and McLane/KeHE, and is live on Amazon, TikTok Shop, Walmart Marketplace, Facebook Shop, Instagram Shop, and YouTube Store. Founded by Reilly Schueler.
Investor Relations: invest@veracorcapital.com | Media: media@veracorgroup.com | Riize: reilly@riizeup.com · (702) 849-2200
This press release contains forward-looking statements within the meaning of applicable securities laws. The Kure Health Ecosystem Fund and Riize Expansion Fund are offered exclusively to accredited investors pursuant to applicable U.S. securities regulations including Regulation D, Rule 506(c). This is not an offer to sell or a solicitation of an offer to buy securities. No binding agreement regarding the B. Taylor partnership has been executed as of the date of this release. Past operating experience is not indicative of future fund performance.
